News|Articles|August 21, 2009

NIR Prediction of Solid Dosage Form Dissolution Profiles - Foss Whitepaper

External Link - article-620799.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

AAPS PharmSci 360: CMC Strategies, Part 1

ByAlfred Rumondor, PhD,Swita Singh, PhD,Susan Haigney

September 2nd 2026

Medical award concept, winner cup on the desk | Image Credit: ©BillionPhotos.com -stock.adobe.com

CPHI Milan Names 2026 Pharma Awards Finalists

BySusan Haigney

September 1st 2026

Regulatory Roundup—August 2026

BySusan Haigney

August 31st 2026

n-nitrosodimethylamine molecular structure, 3d model molecule, dimethylnitrosamine, structural chemical formula view from a microscope | Image Credit: ©Сергей Шиманович -stock.adobe.com

From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

ByChris Williams

August 31st 2026

Lilly and Samsung Biologics make important moves in Pharma M&A

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

ByZachary Zubulake

August 31st 2026

NIR Prediction of Solid Dosage Form Dissolution Profiles - Foss Whitepaper

Related Content

AAPS PharmSci 360: CMC Strategies, Part 1

CPHI Milan Names 2026 Pharma Awards Finalists

Regulatory Roundup—August 2026

From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

Trending on Pharmaceutical Technology

CPHI Milan Names 2026 Pharma Awards Finalists

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

From Phase 1 Screening to Commercial Strategy: Selecting the Right Amorphous Solid Dispersion Technology Early

Regulatory Roundup—August 2026